Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
86 hedge funds and large institutions have $663M invested in Adaptimmune Therapeutics in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 12 closing their positions.
219% more call options, than puts
Call options by funds: $2.08M | Put options by funds: $654K
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
13% more funds holding
Funds holding: 76 → 86 (+10)
5% more capital invested
Capital invested by funds: $631M → $663M (+$32.9M)
0.17% less ownership
Funds ownership: 35.96% → 35.79% (-0.17%)
23% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DWA
Dorsey Wright & Associates
Pasadena,
California
|
+$7.29M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$5.83M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$4.91M |
| 4 |
BAMCO Inc
New York
|
+$4.31M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$3.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.84M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$7.49M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.03M |
| 4 |
QF
QVT Financial
New York
|
-$4.49M |
| 5 |
GAMA
Graticule Asia Macro Advisors
New York
|
-$4.2M |
ADAP Hedge Fund Activity: Q2 2018 in Review
86 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2018, worth a combined $663M — up 5.2% from $631M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ADAP positions and 12 closed out — a net gain of 10 holders — while 20 added to existing stakes and 26 trimmed.
The largest buyer was Dorsey Wright & Associates, opening a new position worth an estimated $7.29M. The largest seller was Millennium Management, cutting an estimated $7.84M.
- 86 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2018, up from 76 in Q1 2018.
- Funds reported $663M of Adaptimmune Therapeutics stock for Q2 2018, up 5.2% quarter-over-quarter.
- 22 funds opened new Adaptimmune Therapeutics positions in Q2 2018 and 12 closed out, a net change of +10 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2018 was Dorsey Wright & Associates, an estimated $7.29M added.
- The largest Adaptimmune Therapeutics seller in Q2 2018 was Millennium Management, an estimated $7.84M sold.
Based on aggregated 13F filings for Q2 2018.